The imidazodiazepinone core is ubiquitous in various
natural and synthetic pharmaceuticals4 as well as vital
intermediates in the synthesis of pentostanin5 and
coformycin,6 both naturally occurring anticancer and
antiviral nucleosides. The commercially available drug
bretazenil7 is used as a partial agonist for GABAA receptors
due to its high affinity to the benzodiazepinone binding site.
On the other hand, flumazenil8 is a high-affinity GABAA-BZ
site antagonist that has been used clinically to treat
benzodiazepine intoxication9 (Figure 1). Most synthetic
approaches toward imidazo[1,4]diazepinones involve multi-
ple-step sequences and harsh conditions and are limited in
scope of the substitution pattern of the scaffold.10 Conse-
quently, it would be highly desirable to develop a more
versatile and milder route for these compounds. Through
the years, multicomponent reactions (MCRs)11 have
received increasing attention due to their simplicity, effi-
ciency, atom economy, shortend reaction times, and the
possibilty for diversity-oriented synthesis. The combination
of MCRs with transition metal-catalysis gives access to
Table 1. Optimization of the Reaction Conditionsa
time conversionb
solvent (h) (%) (yield %)
entry
catalyst (mol %)
AuCl (10)
1
2
3
4
5
CDCl3
CDCl3
CDCl3
CDCl3
CDCl3
CDCl3
CDCl3
CDCl3
CDCl3
24
24
24
10
24
24
4
100 (80)
100 (72)
20
AuCl3(10)
Au(PPh3)Cl (10)
Au(PPh3)OTf (10)
Au(PPh3)SbF6(10)
100 (96)
60
6c Au(PPh3)BF4(10)
65
7
8
9
Au(PPh3)BF4(10)
Au(PPh3)NTf2(10)
Au(X-PhOS)NTf2(10)
100 (98)
100 (96)
100(92)
100 (90)
100(84)
0
24
12
24
24
24
24
24
6
10 [MeCN(JohnPhos)Au] SbF6 (10) CDCl3
11 AgBF4 (10)
CDCl3
CDCl3
CDCl3
CDCl3
ACN-d3
12 Cu(I)OTf (10)
13 Sc(III)(OTf)3 (10)
14 Bi(III)(OTf)3 (10)
15 Au(PPh3)BF4(10)
16 Au(PPh3)BF4(10)
17 Au(PPh3)BF4(5)
18
(4) (a) Showalter, H. D. H.; Putt, S. R.; Borondy, P. E.; Shillis, J. L.
J. Med. Chem. 1983, 26, 1478. (b) Saville-Stones, E. A.; Turner, R. M.;
Lindell, S. D.; Jennings, N. S.; Head, J. C.; Carver, D. S. Tetrahedron 1994,
50, 6695. (c) Kasibhatla, S. R.; Bookser, B. C.; Xiao, W.; Erion, M. D.
J. Med. Chem. 2001, 44, 613. (d) Bookser, B. C.; Kasibhatla, S. R.; Erion,
M. D. J. Med. Chem. 2000, 43, 1519. (e) Kasibhatla, S. R.; Bookser, B. C.;
Probst, G.; Appleman, J. R.; Erion, M. D. J. Med. Chem. 2000, 43, 1508.
(f) Kasibhatla, S. R.; Bookser, B. C.; Appleman, J. R.; Erion, M. D.
J. Med. Chem. 2000, 43, 1495. (g) Erion, M. D.; Kasibhatla, S. R.; Bookser,
B. C.; van Poejie, P. D.; Reddy, M. R.; Gruber, H. E.; Appleman,
5
25
100 (86)
90
THF-d8 24
CDCl3
CDCl3
24
24
45
traces
a All reactions were run on a 0.13 mmol scale of 5a in a screw-capped
vial at 70 °C. b Conversion based on 1H NMR analysis; yields given in
parentheses are isolated yields. c Reaction at 50 °C. Tf = Trifluoro-
methanesulfonyl, X-Phos =2-dicyclohexylphosphino-204060-triisopro-
pylbiphenyl, JohnPhos = (2-biphenyl)di-tert-butylphosphine, PMB =
p-methoxybenzyl.
ꢀ
J. R. J. Am. Chem. Soc. 1999, 121, 308. (h) Kiec-Kononowicza,
€
K.; Karolak-Wojciechowskab, J.; Mullerc, C. E.; Schumacher, B.;
~
Pekalaa, E.; Szymanskaa, E. Eur. J. Med. Chem. 2001, 36, 407.
(I)Chen, B-C;Chao,S. T;Sundeen, J. E.;Tellew, J.;Ahmad,S.Tetrahedron
Lett. 2002, 43, 1595.
(5) Baker, D. C.; Putt, S. R. J. Am. Chem. Soc. 1979, 101, 6127.
Showalter, H. D. H.; Putt, S. R. Tetrahedron Lett. 1981, 22, 3155. Chan,
E.; Putt, S. R.; Showalter, H. D. H.; Baker, D. C. J. Org. Chem. 1982, 47,
3457.
(6) Hawkins, L. D.; Hanvey, J. C.; Boyd, F. L., Jr.; Baker, D. C.
Nucleosides Nucleotides 1983, 2, 479.
(7) Tashma, Z.; Raveh, L.; Liani, H.; Alkalay, D.; Givoni, S.; Kapon,
J.; Cohen, G.; Alcalay, M.; Grauer, E. J. Appl. Toxicol. 2001, 21, S115.
(8) (a) Lancel, M.; Steiger, A. Angew. Chem., Int. Ed. 1999, 111, 2852.
(b) Moran, M. D.; Wilson, A. A.; Elmore, C. S.; Parkes, J.; Ng, A.;
Sadovski, O.; Graff, A.; Daskalakis, Z. J.; Houle, S.; Chapdelaine, M. J.;
Vasdev, N. Bioorg. Med. Chem. 2012, 20, 4482.
(9) Lheureux, P.; Askenasi, R. Hum. Toxicol. 1988, 7, 165.
(10) (a) Achermann, G.; Ballard, T. M.; Blasco, F.; Broutin, P.-E.;
Buttelmann, B.; Fischer, H.; Graf, M.; Hernandez, M.-C.; Hilty, P.;
Knoflach, F.; Koblet, A.; Knust, H.; Kurt, A.; Martin, J. R.; Masciadri,
R.; Porter, R. H. P.; Stadler, H.; Thomas, A. W.; Trube, G.; Wichmann,
J. Bioorg. Med. Chem. Lett. 2009, 19, 5746. (b) Watjen, F.; Baker, R.;
Engelstoff, M.; Herbert, R.; MacLeod, A.; Knight, A.; Merchant, K.;
Moseley, J.; Saunders, J.; Swain, C. J.; Wong, E.; Springer, J. P. J. Med.
Chem. 1989, 32, 2282. (c) Zhang, P.; Zhang, W.; Liu, R.; Harris, B.;
Skolnick, P.; Cook, J. M. J. Med. Chem. 1995, 38, 1679. (d) Li, X.; Cao,
H.; Zhang, C.; Furtmueller, R.; Fuchs, K.; Huck, S.; Sieghart, W.;
Deschamps, J.; Cook, J. M. J. Med. Chem. 2003, 46, 5567. (e) Li, X.; Yu,
J.; Atack, J. R.; Cook, J. M. Med. Chem. Res. 2004, 13, 259. (f) Marcos,
A.; Pedregal, C.; Avendailo, C. Tetrahedron 1991, 41, 1459. (g) Rogers-
Evans, M.; Spurr, P.; Hennig, M. Tetrahedron Lett. 2003, 44, 2425.
(h) Donohue, S. R.; Dannals, R. F. Tetrahedron Lett. 2009, 50, 7271.
complex molecules in few steps as compared to traditional
multistep processes. We have recently developed a sequen-
tial post-Ugi gold(I)-catalyzed intramolecular hydroar-
ylation approach for the synthesis of indolazocines,12
spiroindolines,13 pyrroloazepinones, and pyrrolopyridi-
nones.14 Inspired by these findings and as a result of our
interest in exploring the synthetic utility of both transi-
tion metal catalysis15 and multicomponent reactions,16 we
have developed an expedient post-Ugi intramolecular
(12) Modha, S. G.; Vachhani, D. D.; Jacobs, J.; Van Meervelt, L.;
Van der Eycken, E. V. Chem. Commun. 2012, 48, 6550.
(13) Modha, S. G.; Kumar, A.; Vachhani, D. D.; Jacobs, J.; Sharma,
S. K.; Parmar, V. S.; Van Meervelt, L.; Van der Eycken, E. V. Angew.
Chem., Int. Ed. 2012, 51, 9572.
(14) Modha, S. G.; Kumar, A.; Vachhani, D. D.; Jacobs, J.; Sharma,
S. K.; Parmar, V. S.; Van Meervelt, L.; Van der Eycken, E. V. Chem.
Commun. 2012, 48, 10916.
(15) (a) Modha, S. G.; Trivedi, J. C.; Mehta, V. P.; Ermolat’ev, D. S.;
Van der Eycken, E. V. J. Org. Chem. 2011, 76, 846. (b) Mehta, V. P.; Van
der Eycken, E. V. Chem. Soc. Rev. 2011, 40, 4925. (c) Kappe, C. O.; Van
der Eycken, E. V. Chem. Soc. Rev. 2010, 39, 1280. (d) Donets, P. A.; Van
Hecke, K.; Van Meervelt, L.; Van der Eycken, E. V. Org. Lett. 2009, 11,
3618. (e) Donets, P. A.; Van der Eycken, E. V. Synthesis 2011, 2147.
(f) Modha, S. G.; Mehta, V. P.; Ermolat’ev, D. S; Balzarini, J.; Van
Hecke, K.; Van Meervelt, L.; Van der Eycken, E. V. Mol. Diversity 2010,
14, 767.
€
(11) For isonitrile-based multicomponent reactions, see (a) Domling,
€
A.; Ugi, I. Angew. Chem., Int. Ed. 2000, 39, 3168. (b) Domling, A. Chem.
Rev. 2006, 106, 17. For multicomponent reactions with indoles, see:
(c) Shriri, M. Chem. Rev. 2012, 112, 3508. For asymmetric multicompo-
ꢀ
nent reactions, see: (d) Ramon, D. J.; Yus, M. Angew. Chem., Int. Ed.
2005, 44, 1602. For multicomponent reactions in general, see: (e)
Ganem, B. Acc. Chem. Res. 2009, 42, 463. (f) ElKaım, L.; Grimaud,
(16) (a) Mehta, V. P.; Modha, S. G.; Ruijter, E.; Van Hecke, K.; Van
Meervelt, L.; Pannecouque, C.; Balzarini, J.; Orru, R. V. A.; Van der
Eycken, E. V. J. Org. Chem. 2011, 76, 2828. (b) Peshkov, V. A.;
Pereshivko, O. P.; Van der Eycken, E. V. Chem. Soc. Rev. 2012, 41, 3790.
¨
L. Mol. Diversity 2010, 14, 855. (g) Ruijter, E.; Scheffelaar, R.; Orru,
€
R. V. A. Angew.Chem., Int. Ed. 2011, 50, 6234. (h) Domling, A.; Wang,
W.; Wang, K. Chem. Rev. 2012, 112, 3083.
B
Org. Lett., Vol. XX, No. XX, XXXX